• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous (PubMed=9598804).
  
• Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
  

PubMed=6976407; DOI=10.1084/jem.154.6.1764; PMCID=PMC2186539
Anthony P. Albino, Kenneth Oliver Lloyd, Alan N. Houghton, Herbert Friedrich Oettgen, Lloyd John Old;
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient Implications for the study of tumor antigens.
J. Exp. Med. 154:1764-1778(1981)

PubMed=2983346; DOI=10.1073/pnas.82.5.1470; PMCID=PMC397284
Nicholas C. Dracopoli, Alan N. Houghton, Lloyd John Old;
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985)

PubMed=2886213
Nicholas C. Dracopoli, Becky Alhadeff, Alan N. Houghton, Lloyd John Old;
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma.
Cancer Res. 47:3995-4000(1987)

PubMed=1716514
Anthony P. Albino, Brigid M. Davis, David Michael Nanus;
Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.
Cancer Res. 51:4815-4820(1991)

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Graeme J. Walker, Jose F. Flores, J. Michael Glendening, Amy Hsiu-Ti Lin, Isabel D.C. Markl, Jane W. Fountain;
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998)